VEGFA and neoplasm: To evaluate whether the CAM xenograft model can reproduce this intratumoral hypoxic plasticity, we modulated the tumor xenograft vasculature using the anti- and pro-angiogenic treatments, sorafenib, and VEGF, respectively.